Earnings call transcript: Medistim Q2 2025 sees stock surge 14% on strong growth

Medistim ASA reported robust Q2 2025 results, with revenue up 16.7% and operating profit surging 31%, driven by strong performance in the Americas and Asia Pacific regions and increased sales of high-margin own products. This impressive financial showing prompted a 14.35% stock price rally, pushing shares near their 52-week high and reflecting strong investor confidence, albeit at a high earnings multiple. The company's strategic focus on direct market expansion, product innovation, including future AI integration, and commercial team strengthening underpins this growth, positioning Medistim for continued momentum despite minor regional softness and potential tariff impacts.

Analysis

Medistim ASA delivered a robust second quarter for 2025, underscored by a 16.7% year-over-year revenue increase and a 31% surge in operating profit, culminating in a strong EBIT margin of 32%. This performance was driven primarily by exceptional growth in the Americas, which saw a 32.9% currency-neutral sales increase and accounted for over 80% of the total nominal revenue gain, alongside a solid recovery in the Asia Pacific region led by China. A significant contributor to profitability was the favorable shift in product mix towards higher-margin proprietary products, which grew 18.2% and lifted the gross margin to 81.9%. The market reacted positively, with the stock climbing 14.35% to trade near its 52-week high, although analysis indicates it trades at a high earnings multiple, suggesting high growth expectations are already priced in. The company's forward-looking strategy is centered on organic growth through direct market expansion, converting its installed base to higher-value imaging systems, and product innovation, including a long-term ambition for AI integration. While financially sound with moderate debt and strong liquidity, potential risks include a revenue decline in the EMEA region, the delayed launch of its new Intui software, and the impact of potential tariffs, which the company plans to offset with price increases in the second half of the year.

Key Decisions for Investors

• Investors may view the robust 16.7% revenue growth and 31% operating profit increase as strong justification for a bullish stance, particularly as planned second-half price hikes could provide a further catalyst not yet reflected in current earnings.
• Given the stock is trading at a high earnings multiple near its 52-week high, it is crucial to monitor the execution of the Intui software launch and any recovery in the EMEA region, as the current valuation leaves little room for operational missteps.
• Monitor the company's ability to manage rising R&D and commercial expenses while executing its organic growth strategy, specifically focusing on the conversion rate of its installed base to higher-margin imaging systems and progress in its direct market expansion.